These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11001549)

  • 1. Immunohistologic responses within dermal metastatic melanoma lesions of patients treated with a synthetic peptide vaccine.
    Fritsch M; Rosenberg SA; Duray PH
    J Immunother; 2000; 23(5):557-69. PubMed ID: 11001549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
    Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
    Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901.
    Roberts JD; Niedzwiecki D; Carson WE; Chapman PB; Gajewski TF; Ernstoff MS; Hodi FS; Shea C; Leong SP; Johnson J; Zhang D; Houghton A; Haluska FG;
    J Immunother; 2006; 29(1):95-101. PubMed ID: 16365605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.
    Grover A; Kim GJ; Lizée G; Tschoi M; Wang G; Wunderlich JR; Rosenberg SA; Hwang ST; Hwu P
    Clin Cancer Res; 2006 Oct; 12(19):5801-8. PubMed ID: 17020987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion.
    Powell DJ; Dudley ME; Hogan KA; Wunderlich JR; Rosenberg SA
    J Immunol; 2006 Nov; 177(9):6527-39. PubMed ID: 17056585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
    Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA
    Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
    Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
    Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Langerhans' cells and lymphocytic infiltrate in AIDS-associated Kaposi's sarcoma. An immunohistochemical study.
    Valcuende-Cavero F; Febrer-Bosch MI; Castells-Rodellas A
    Acta Derm Venereol; 1994 May; 74(3):183-7. PubMed ID: 7521102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases.
    Panelli MC; Riker A; Kammula U; Wang E; Lee KH; Rosenberg SA; Marincola FM
    J Immunol; 2000 Jan; 164(1):495-504. PubMed ID: 10605047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous melanoma vaccine induces inflammatory responses in melanoma metastases: relevance to immunologic regression and immunotherapy.
    Murphy GF; Radu A; Kaminer M; Berd D
    J Invest Dermatol; 1993 Mar; 100(3):335S-341S. PubMed ID: 8440919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of cellular infiltration in choroidal melanoma.
    Tobal K; Deuble K; McCartney A; Lightman S
    Melanoma Res; 1993 Feb; 3(1):63-5. PubMed ID: 8471838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune selection after antigen-specific immunotherapy of melanoma.
    Riker A; Cormier J; Panelli M; Kammula U; Wang E; Abati A; Fetsch P; Lee KH; Steinberg S; Rosenberg S; Marincola F
    Surgery; 1999 Aug; 126(2):112-20. PubMed ID: 10455872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.
    Mackensen A; Meidenbauer N; Vogl S; Laumer M; Berger J; Andreesen R
    J Clin Oncol; 2006 Nov; 24(31):5060-9. PubMed ID: 17075125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
    Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
    Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.
    Belli F; Testori A; Rivoltini L; Maio M; Andreola G; Sertoli MR; Gallino G; Piris A; Cattelan A; Lazzari I; Carrabba M; Scita G; Santantonio C; Pilla L; Tragni G; Lombardo C; Arienti F; Marchianò A; Queirolo P; Bertolini F; Cova A; Lamaj E; Ascani L; Camerini R; Corsi M; Cascinelli N; Lewis JJ; Srivastava P; Parmiani G
    J Clin Oncol; 2002 Oct; 20(20):4169-80. PubMed ID: 12377960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses.
    Smith JW; Walker EB; Fox BA; Haley D; Wisner KP; Doran T; Fisher B; Justice L; Wood W; Vetto J; Maecker H; Dols A; Meijer S; Hu HM; Romero P; Alvord WG; Urba WJ
    J Clin Oncol; 2003 Apr; 21(8):1562-73. PubMed ID: 12697882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.
    Aarntzen EH; Schreibelt G; Bol K; Lesterhuis WJ; Croockewit AJ; de Wilt JH; van Rossum MM; Blokx WA; Jacobs JF; Duiveman-de Boer T; Schuurhuis DH; Mus R; Thielemans K; de Vries IJ; Figdor CG; Punt CJ; Adema GJ
    Clin Cancer Res; 2012 Oct; 18(19):5460-70. PubMed ID: 22896657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.
    Corbière V; Chapiro J; Stroobant V; Ma W; Lurquin C; Lethé B; van Baren N; Van den Eynde BJ; Boon T; Coulie PG
    Cancer Res; 2011 Feb; 71(4):1253-62. PubMed ID: 21216894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma.
    Kirkwood JM; Mascari RA; Edington HD; Rabkin MS; Day RS; Whiteside TL; Vlock DR; Shipe-Spotloe JM
    Cancer; 2000 Jun; 88(12):2693-702. PubMed ID: 10870051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.